Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Sell
38
ARCT Quote, Financials, Valuation and Earnings
Last price:
$13.32
Seasonality move
:
16.82%
Day range:
$13.00 - $14.53
52-week range:
$8.04 - $25.88
Dividend yield:
0%
P/E ratio:
8.50x
P/S ratio:
2.75x
P/B ratio:
1.55x
Volume:
1.2M
Avg. volume:
477.3K
1-year change:
-45.48%
Market cap:
$361.5M
Revenue:
$138.4M
EPS (TTM):
-$2.53
Analysts' Opinion
-
Consensus RatingArcturus Therapeutics Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $67.10, Arcturus Therapeutics Holdings has an estimated upside of 403.38% from its current price of $13.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $32.00 representing 100% downside risk from its current price of $13.33.
Fair Value
-
According to the consensus of 8 analysts, Arcturus Therapeutics Holdings has 403.38% upside to fair value with a price target of $67.10 per share.
ARCT vs. S&P 500
-
Over the past 5 trading days, Arcturus Therapeutics Holdings has overperformed the S&P 500 by 4.86% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Arcturus Therapeutics Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arcturus Therapeutics Holdings revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Arcturus Therapeutics Holdings reported revenues of $25.5M.
Earnings Growth
-
Arcturus Therapeutics Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Arcturus Therapeutics Holdings reported earnings per share of -$0.52.
Enterprise value:
159.6M
EV / Invested capital:
--
Price / LTM sales:
2.75x
EV / EBIT:
42.21x
EV / Revenue:
1.22x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.78x
Price / Operating cash flow:
76.35x
Enterprise value / EBITDA:
34.45x
Gross Profit (TTM):
--
Return On Assets:
-18.39%
Net Income Margin (TTM):
-51.96%
Return On Equity:
-27.08%
Return On Invested Capital:
-26.76%
Operating Margin:
-66.04%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $280.2M | $110.6M | $131.3M | $32.6M | $25.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $77.3M | -$123.4M | -$82.1M | -$30.4M | -$16.8M | |
| EBITDA | $116.1M | -$65.6M | -$60.2M | -$29.5M | -$16M | |
| Diluted EPS | $4.15 | -$3.91 | -$2.53 | -$1.00 | -$0.52 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $470M | $327M | $424.6M | $375.8M | $278.8M | |
| Total Assets | $481.5M | $342M | $470.9M | $418.8M | $331.8M | |
| Current Liabilities | $53.3M | $107.3M | $90.1M | $115.4M | $49.4M | |
| Total Liabilities | $128.9M | $157.2M | $141.6M | $154.9M | $98M | |
| Total Equity | $352.6M | $184.7M | $329.2M | $264M | $233.8M | |
| Total Debt | $61.3M | $63.5M | -- | -- | $15M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $45.2M | $12.2M | -$89.3M | -$5.6M | -$35.1M | |
| Cash From Investing | -$6.3M | -$2.5M | -$545K | -$240K | -$137K | |
| Cash From Financing | -$30.6M | $5.5M | $18.4M | $2.2M | $15.2M | |
| Free Cash Flow | $38.9M | $9.8M | -$89.9M | -$5.8M | -$35.3M | |
ARCT
Sector
Market Cap
$361.5M
$33.5M
Price % of 52-Week High
51.51%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-45.48%
-35.33%
Beta (5-Year)
2.298
0.631
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$13.07
200-day SMA
Sell
Level
$15.99
Bollinger Bands (100)
Buy
Level
10.84 - 15.36
Chaikin Money Flow
Sell
Level
-63.6M
20-day SMA
Buy
Level
$12.78
Relative Strength Index (RSI14)
Buy
Level
55.04
ADX Line
Buy
Level
25.49
Williams %R
Neutral
Level
-51.8248
50-day SMA
Buy
Level
$12.29
MACD (12, 26)
Buy
Level
0.37
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
64.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.3051)
Sell
CA Score
(Annual)
Level (-0.4806)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4462)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
Stock Forecast FAQ
In the current month, ARCT has received 8 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARCT average analyst price target in the past 3 months is $67.10.
-
Where Will Arcturus Therapeutics Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arcturus Therapeutics Holdings share price will rise to $67.10 per share over the next 12 months.
-
What Do Analysts Say About Arcturus Therapeutics Holdings?
Analysts are divided on their view about Arcturus Therapeutics Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arcturus Therapeutics Holdings is a Sell and believe this share price will drop from its current level to $32.00.
-
What Is Arcturus Therapeutics Holdings's Price Target?
The price target for Arcturus Therapeutics Holdings over the next 1-year time period is forecast to be $67.10 according to 8 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arcturus Therapeutics Holdings is a Buy. 8 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARCT?
You can purchase shares of Arcturus Therapeutics Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arcturus Therapeutics Holdings shares.
-
What Is The Arcturus Therapeutics Holdings Share Price Today?
Arcturus Therapeutics Holdings was last trading at $13.32 per share. This represents the most recent stock quote for Arcturus Therapeutics Holdings. Yesterday, Arcturus Therapeutics Holdings closed at $13.33 per share.
-
How To Buy Arcturus Therapeutics Holdings Stock Online?
In order to purchase Arcturus Therapeutics Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did David Tepper Sell NVIDIA Stock?
In Q1, billionaire David Tepper of Appaloosa Management sold nearly…
Why Is Planet Labs Stock Up Today?
Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
